6-氨基吲哚

• 产品号: 630721
• CAS号: 5318-27-4
• 分子式: C8H8N2
• 分子量: 132.16252
• 纯 度: 97%

产品别名

• 标题: 6-Aminoindole
• IUPAC标准名: 1H-indol-6-amine
• IUPAC传统名: 1H-indol-6-amine
• 别名: Indol-6-ylamine; NSC 82379

产品登记号

• CAS号: 5318-27-4
• PubChem SID: 24882337
• MDL号: MFCD02093959

产品性质

• Empirical Formula (Hill Notation): C8H8N2
• 纯度: 97%
• 熔点: 75-79 °C
• GHS警示词: Warning
• GHS危险声明: H302-H315-H319-H335
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• GHS警示性声明: P261-P305 + P351 + P338
• 危险公开号: 22-36/37/38
• 安全公开号: 26-36
• 保存温度: -20°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Packaging
1, 5 g in glass bottle
Application
Reactant for preparation of:
• Inhibitors of mammalian target of rapamycin (mTOR ) protein1
• Inhibitors of the AcrAB-TolC efflux pump2
• Inhibitors of Gli1-mediated transcription in the Hedgehog pathway3
• Potent DNA-topoisomerase II poisons and anti-MDR agents4
• Protein kinase C θ (PKCθ) inhibitors5
• Piperidine carboxamide as transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists6
• Potent and selective blockers of the Nav1.8 sodium channel as potential analgesics for the treatment of neuropathic and inflammatory pain7
• 5,6-fused heteroaromatic ureas as TRPV1 antagonists8
• Allosteric enhancers of the A3 adenosine receptor9
• Human liver glycogen phosphorylase (HLGP) inhibitors for the treatment of type 2 diabetes10

详细说明 (简体中文)

包装
1, 5 g in glass bottle
Application
Reactant for preparation of:
• Inhibitors of mammalian target of rapamycin (mTOR ) protein1
• Inhibitors of the AcrAB-TolC efflux pump2
• Inhibitors of Gli1-mediated transcription in the Hedgehog pathway3
• Potent DNA-topoisomerase II poisons and anti-MDR agents4
• Protein kinase C θ (PKCθ) inhibitors5
• Piperidine carboxamide as transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists6
• Potent and selective blockers of the Nav1.8 sodium channel as potential analgesics for the treatment of neuropathic and inflammatory pain7
• 5,6-fused heteroaromatic ureas as TRPV1 antagonists8
• Allosteric enhancers of the A3 adenosine receptor9
• Human liver glycogen phosphorylase (HLGP) inhibitors for the treatment of type 2 diabetes10